HEB, Hemispherx Biopharma (AMEX)NEW Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : HEB, Hemispherx Biopharma (AMEX)NEW

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Graham Marshman who wrote (94)	11/24/1997 9:38:00 AM
From: MarcG	Read Replies (1) of 857

A Valuation Analysis of Hemispherx's product pipeline was recently updated by one of their lead analysts, J. Abella, of Westergaard Abella. For the complete outline, go to: westergaard.com:8080/Med/Valuation/valhemi9745.htm The analysis states; "The shares of HEB have already discounted failure for Ampligen for the CFS indication even though the company is generating revenues from clinical trials of the product". The marginal new highs being set by HEB may indicate that this discounting process is over, and the shares may be entering a new phase characterized by anticipation of possible positive clinical phase III trial results and subsequent FDA approval, exhibited by increased speculation and institutional sponsorship in the shares. While at First Honolulu Securities, David Watumull, was the analyst responsible for a HEMX (now, HEB) buy write-up and recommendation, as well as a 50+ page analysis of the technology platform. MG:

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next